peginterferon

In this episode, Nancy Reau, MD, discusses new data on hepatitis B virus presented at AASLD 2023, including:

• Current therapies
  • Studies 108 and 110: Factors Linked With Lack of Virologic Suppression After 8 Yr of TAF or TDF
  • Kaiser Permanente Northern California: HCC or Death With TDF vs ETV for Chronic Hepatitis B
  • Early vs Late Postpartum Cessation of TDF Initiated for Prevention of Vertical HBV Transmission
• Investigational functional cure strategies
  • B-Together: Sequential Bepirovirsen and PegIFN Added to NA Therapy for Chronic HBV Infection
  • MARCH Part B: VIR-3434 ± VIR-2218 ± PegIFN Added to NA Therapy for Chronic HBV Infection
  • REEF-IT: JNJ-3989 + NA ± JNJ-6379 With PegIFN Add-on Consolidation in Patients With HBeAg-Positive CHB
  • HBV003: VTP-300 + Nivolumab Added to NA Therapy for Chronic HBV Infection
  • CVP-NASVAC: Nasally Administered Therapeutic Vaccine for Chronic HBV Infection

Presenter:
Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center 
Chicago, Illinois

Link to full program: 
https://bit.ly/47XJlU4

In this episode, Stefan Zeuzem, MD, discusses new data on viral hepatitis presented at EASL 2023, including:

• Hepatitis B virus
  • Durability of response with bepirovirsen
  • HBsAg loss with siRNA VIR-2218 combined with either VIR-3434 (novel monoclonal antibody) or pegIFN-alfa
• Hepatitis delta virus
  • 96-week follow-up of immediate vs delayed bulevirtide
  • Off-treatment response for lonafarnib + ritonavir ± pegIFN-alfa 
  • Safety and efficacy outcomes with siRNA JNJ-3989 + nucleos(t)ide analogue
• Hepatitis C virus
  • Collaborative service at opiate substitution treatment clinic to improve linkage to care in Ireland
  • Nurse-led test-and-treat program to increase screening and diagnosis at female prisons in the United Kingdom
  • FIND-C study using machine learning to improve screening-to-diagnosis ratio using clinical factors and social determinants of health

Presenter:

Stefan Zeuzem, MD
Professor of Medicine 
Chief, Department of Medicine 
JW Goethe University Hospital 
Frankfurt, Germany

Link to full program: 

https://bit.ly/3JQQj3J

In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include:

• Patient presentation and goals of frontline therapy
• Considerations for second-line therapy in the setting of treatment intolerance
• Experts’ thoughts on the potential of early intervention to alter disease progression

Presenters:

Raajit Rampal, MD, PhD
Associate Member
Associate Attending Physician
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.

Link to the full program, including downloadable slides and an on-demand webcast from the live event:
https://bit.ly/3X3x6jX

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from AASLD 2022, including:

• Hepatitis B
• Prevention of HBV vertical transmission when HBIg is unavailable
• Therapeutic vaccination for HBV cure
• Antiviral therapy to prevent HCC in patients with CHB in the indeterminate phase
• Hepatitis delta
• HDV prevalence in ethnically diverse, urban, safety-net populations
• Bulevirtide ± pegIFN-α2a for chronic HDV in the French cATU study
• Bulevirtide monotherapy for patients with HDV and compensated cirrhosis in the HEP4Di study
• HDV functional cure with lonafarnib-based therapy
• Hepatitis C
• Integrated community HCV service for PWUD: the ITTREAT study
• Helios-3 study of treatment of people with HCV by specialists or nonspecialists
• Risk of HCC after SVR in patients with HCV

Presenter:

Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I 
JW Goethe University Hospital 
Frankfurt, Germany

Follow along with the downloadable slideset at: 
https://bit.ly/3FxIOwZ

Link to full program: 
https://bit.ly/3Y1tD6f

You can think of the “D” in HDV as standing for difficult, disadvantaged, and dangerous. Hepatitis delta virus (HDV) is difficult to diagnose, is often diagnosed in disadvantaged patient populations, and leads to dangerous sequelae.

Listen as Dr. Kosh Agarwal and Dr. Graham R. Foster and discuss challenges and opportunities for linking patients to care after a positive test for HDV.

Presenters:

Kosh Agarwal, MD
Consultant Hepatologist and Transplant Physician
Institute of Liver Studies
King's College Hospital NHS Foundation Trust
London, United Kingdom

Graham R. Foster, FRCP, PhD
Professor of Hepatology
The Liver Unit
Consultant Hepatologist
Queen Mary University of London
London, United Kingdom

Link to full program:
https://bit.ly/3tlxa0H

Hepatitis delta virus (HDV) is the most severe form of viral hepatitis, yet many patients go undiagnosed. Increasing HDV awareness is an important step to correct this and ensure that at-risk patients receive screening and then treatment and monitoring following a positive test. Hear Grace LH Wong, MD, and Ming-Lung Yu, MD, PhD, discuss a call to action to increase healthcare professional and patient awareness of HDV. 

Presenters: 

Grace LH Wong, MD
Professor
Director, Medical Data Analytics Centre (MDAC)
Deputy Director, Center for Liver Health
Assistant Dean (Learning Experience), Faculty of Medicine
The Chinese University of Hong Kong
Honorary Consultant
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
Prince of Wales Hospital
Hong Kong

Ming-Lung Yu, MD, PhD
Chair Professor
Hepatobiliary Division
Department of Internal Medicine and Hepatitis Center
Kaohsiung Medical University
Visiting Staff
Hepatobiliary Division
Department of Internal Medicine
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan

Link to full program: 
https://bit.ly/3tlxa0H

Hepatitis delta virus (HDV) is the most severe form of viral hepatitis and warrants new treatment options for better efficacy and tolerability. In part 2 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on new and emerging treatment options for HDV and rational use of these new agents. Their discussion includes:

• Assembly inhibitors (eg, lonafarnib)
• Entry inhibitors (eg, bulevirtide)
• Interferon lambda
• Nucleic acid polymers
• Small interfering RNA (siRNA) agents

Presenters: 

Heiner Wedemeyer, MD
Professor and Chairman
Department of Gastroenterology, Hepatology, and Endocrinology
Hannover Medical School
Hannover, Germany

Cihan Yurdadin, MD
Professor and Chief
 Department of Gastroenterology and Hepatology
Koç University Medical School
Istanbul, Turkey

Link to full program:
https://bit.ly/365VUlG

Hepatitis delta virus (HDV) only exists in patients with hepatitis B virus (HBV) coinfection. In part 1 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on serologic testing for both HDV and HBV and steps to take in monitoring, treating, and reassessing HBV in patients coinfected with HDV.

Presenters:

Heiner Wedemeyer, MD
Professor and Chairman
Department of Gastroenterology, Hepatology, and Endocrinology
Hannover Medical School
Hannover, Germany

Cihan Yurdaydin, MD
Professor and Chief, Department of Gastroenterology and Hepatology
Koç University Medical School
Istanbul, Turkey

Link to full program:
https://bit.ly/365VUlG

Treatment options for hepatitis delta virus (HDV) are lacking, but many exciting agents are under investigation. Hear Drs Nancy Reau and Stefan Zeuzem discuss their thoughts on up-and-coming agents for treating HDV, and explore what questions need answering to most effectively use currently available and emerging therapies, which include:

• Bulevirtide
• Interferon λ
• Lonafarnib

Presenters:

Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany

Link to full program:
https://bit.ly/3tlxa0H